StoneX Group’s MiNK Therapeutics INKT Stock Holding History

StoneX Group’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,112	Closed	-$55.1K	–	761
2022 Q4	$55.1K	Buy	+2,112	New	+$49.6K	0.01%	521

Other funds holding INKT

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group's INKT Position: Q1 2023 in Review

StoneX Group sold out of MiNK Therapeutics (INKT) in Q1 2023, closing a stake of 2,112 shares — an estimated $55.1K sold.

StoneX Group first reported a position in INKT in Q4 2022 and held it in 1 quarter. The position peaked at $55.1K in Q4 2022. 12 funds tracked by Wall St. Rank hold INKT as of Q1 2023.

StoneX Group reported no remaining MiNK Therapeutics position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 2,112 MiNK Therapeutics shares in Q1 2023, an estimated $55.1K.
StoneX Group first reported a position in MiNK Therapeutics in Q4 2022 and held it in 1 quarter.
StoneX Group's MiNK Therapeutics position peaked at $55.1K in Q4 2022.
12 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.